Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Orexo AB (publ)

ORXOYPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$2.96
$0.16(5.71%)
U.S. Market opens in 7h 53m

Orexo AB (publ) Fundamental Analysis

Orexo AB (publ) (ORXOY) shows weak financial fundamentals with a PE ratio of -7.16, profit margin of -33.69%, and ROE of 5.65%. The company generates $0.4B in annual revenue with weak year-over-year growth of -7.64%.

Key Strengths

Cash Position885.95%
PEG Ratio-0.02
Current Ratio3.70

Areas of Concern

ROE5.65%
Operating Margin-39.77%
We analyze ORXOY's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 0.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
0.9/100

We analyze ORXOY's fundamental strength across five key dimensions:

Efficiency Score

Weak

ORXOY struggles to generate sufficient returns from assets.

ROA > 10%
-10.00%

Valuation Score

Excellent

ORXOY trades at attractive valuation levels.

PE < 25
-7.16
PEG Ratio < 2
-0.02

Growth Score

Weak

ORXOY faces weak or negative growth trends.

Revenue Growth > 5%
-7.64%
EPS Growth > 10%
-57.91%

Financial Health Score

Moderate

ORXOY shows balanced financial health with some risks.

Debt/Equity < 1
1.00
Current Ratio > 1
3.70

Profitability Score

Weak

ORXOY struggles to sustain strong margins.

ROE > 15%
5.65%
Net Margin ≥ 15%
-33.69%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is ORXOY Expensive or Cheap?

P/E Ratio

ORXOY trades at -7.16 times earnings. This suggests potential undervaluation.

-7.16

PEG Ratio

When adjusting for growth, ORXOY's PEG of -0.02 indicates potential undervaluation.

-0.02

Price to Book

The market values Orexo AB (publ) at 1.90 times its book value. This may indicate undervaluation.

1.90

EV/EBITDA

Enterprise value stands at -16.10 times EBITDA. This is generally considered low.

-16.10

How Well Does ORXOY Make Money?

Net Profit Margin

For every $100 in sales, Orexo AB (publ) keeps $-33.69 as profit after all expenses.

-33.69%

Operating Margin

Core operations generate -39.77 in profit for every $100 in revenue, before interest and taxes.

-39.77%

ROE

Management delivers $5.65 in profit for every $100 of shareholder equity.

5.65%

ROA

Orexo AB (publ) generates $-10.00 in profit for every $100 in assets, demonstrating efficient asset deployment.

-10.00%

Following the Money - Real Cash Generation

Operating Cash Flow

Orexo AB (publ) generates strong operating cash flow of $189.12M, reflecting robust business health.

$189.12M

Free Cash Flow

Orexo AB (publ) generates strong free cash flow of $188.32M, providing ample flexibility for dividends, buybacks, or growth.

$188.32M

FCF Per Share

Each share generates $5.43 in free cash annually.

$5.43

FCF Yield

ORXOY converts 20.27% of its market value into free cash.

20.27%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-7.16

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.02

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.90

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.41

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.003

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.70

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

5.65

vs 25 benchmark

ROA

Return on assets percentage

-0.10

vs 25 benchmark

ROCE

Return on capital employed

-0.16

vs 25 benchmark

How ORXOY Stacks Against Its Sector Peers

MetricORXOY ValueSector AveragePerformance
P/E Ratio-7.1629.78 Better (Cheaper)
ROE565.16%792.00% Weak
Net Margin-33.69%-23280.00% (disorted) Weak
Debt/Equity1.000.25 Weak (High Leverage)
Current Ratio3.704.60 Strong Liquidity
ROA-10.00%-18077.00% (disorted) Weak

ORXOY outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Orexo AB (publ)'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-29.84%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-193.07%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-111.41%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ